InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE:…
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF
SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
The new technology is the world's smallest, catheter-delivered defibrillation leadAUSTIN, Texas, Feb.…
Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform
LEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a…
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell…
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17,…
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision…
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping…
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE,…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
